文献速递其他结缔组织病

系统性硬化症中癌症的发病率、危险因素与结局

Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2020-01-01

基于澳大利亚1,727例系统性硬化症(SSc)队列,癌症年发病率为1.3%、患病率14.2%,标准化发病比(SIR)为2.15(95%CI 1.84-2.49)。抗RNA聚合酶III抗体与SSc发病5年内确诊癌症风险升高相关,ILD与肺癌相关;合并癌症者死亡风险增加逾2倍,年人均超额医疗费用1,496澳元。

要点

  • SSc患者癌症总体风险升高,SIR为2.15(95%CI 1.84-2.49)。
  • 抗RNAP抗体者SSc发病5年内癌症风险升高(OR 2.9,P=0.044)。
  • 合并癌症的SSc患者死亡风险升高(HR 2.85,95%CI 1.51-5.37)。

核心结论

  • SSc患者癌症发病风险升高,尤其ILD相关肺癌及抗RNAP抗体阳性者发病早期出现的乳腺癌和黑色素瘤。
  • 合并癌症的SSc患者较无癌症者死亡率更高、医疗费用更高,年人均超额费用1,496澳元(P<0.001)。

研究设计与样本

  • 澳大利亚SSc队列研究,共1,727例,计算相对一般人群的标准化发病比(SIR)与标准化死亡比。
  • 采用Cox比例风险回归比较合并与不合并癌症的SSc患者生存,logistic回归识别癌症决定因素,并通过跨辖区数据链接量化医疗费用。

主要发现

  • 癌症年发病率为1.3%,患病率14.2%,SIR为2.15(95%CI 1.84-2.49)。
  • 最常见癌症为乳腺癌、黑色素瘤、血液系统肿瘤和肺癌。
  • 抗RNAP抗体与癌症风险升高相关(OR 2.9,P=0.044),癌症在SSc发病5年内确诊。
  • 钙通道阻滞剂与总体癌症(OR 1.47,P=0.016)、乳腺癌(OR 1.61,P=0.051)和黑色素瘤(OR 2.01,P=0.042)风险升高相关。
  • ILD与肺癌相关(OR 2.83,P=0.031)。

关键数值与推荐

  • SIR 2.15(95%CI 1.84-2.49),对应SSc队列相对澳大利亚一般人群的癌症发病风险。
  • 合并癌症的SSc患者死亡风险:HR 2.85(95%CI 1.51-5.37),P=0.001。
  • 年人均超额医疗费用1,496澳元(P<0.001)。

临床怎么用

  • 对SSc患者应关注癌症筛查,尤其合并ILD者警惕肺癌、抗RNAP抗体阳性者关注发病早期乳腺癌与黑色素瘤。
  • 评估钙通道阻滞剂使用与癌症风险的关联,并关注合并癌症者的死亡风险与医疗负担。

局限性

  • 原文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify the burden of cancer in systemic sclerosis (SSc). METHODS: Standardized incidence ratios (SIRs) and standardized mortality ratios relative to the general Australian population were derived. Cox proportional hazards regression was used to estimate survival in patients with SSc with cancer compared to patients without. Determinants of cancer were identified using logistic regression. Health care cost was quantified through cross-jurisdictional data linkage. RESULTS: This SSc cohort of 1,727 had a cancer incidence of 1.3% per year and a prevalence of 14.2%, with a SIR of 2.15 (95% confidence interval [95% CI] 1.84-2.49). The most common cancers were breast, melanoma, hematologic, and lung. Anti-RNA polymerase III (RNAP) antibody was associated with an increased risk of cancer (odds ratio [OR] 2.9, P = 0.044), diagnosed within 5 years of SSc disease onset. Calcium channel blockers were associated with a higher risk of overall cancer (OR 1.47, P = 0.016), breast cancer (OR 1.61, P = 0.051), and melanoma (OR 2.01, P = 0.042). Interstitial lung disease (ILD) was associated with lung cancer (OR 2.83, P = 0.031). Incident SSc cancer patients had >2-fold increased mortality compared to patients with SSc without cancer (hazard ratio 2.85 [95% CI 1.51-5.37], P = 0.001). Patients with SSc and cancer utilized more health care than those without cancer, with an excess annual health care cost of $1,496 Australian (P < 0.001). CONCLUSION: SSc carries an increased risk of developing cancer, particularly lung cancer associated with ILD, and breast cancer and melanoma occurring close to SSc disease onset in association with RNAP antibodies. Compared to those patients without cancer, patients with SSc and cancer had higher mortality and an increased health care cost, with an annual excess per patient cost of $1,496 Australian (P < 0.001).

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Morrisroe K, Hansen D, Huq M, et al. Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2020. PMID: 31539207. doi:10.1002/acr.24076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。